Diagnostyka neowaskularyzacji plamkowej typu 3 Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2021
Słowa kluczowe:
wysiękowa postać zwyrodnienia plamki związanego z wiekiem, neowaskularyzacja plamkowa, angiografia oparta na optycznej koherentnej tomografii, terapia anty-VEGF
##plugins.themes.bootstrap3.article.main##
Abstrakt
Neowaskularyzacja plamkowa typu 3 charakteryzuje się kompleksem patologicznych naczyń zlokalizowanych w siatkówce sensorycznej. W badaniu dna oka objawia się jako wylewy śródsiatkówkowe, obrzęk w plamce, wysięki twarde i odwarstwienia nabłonka barwnikowego. Do diagnostyki i monitorowania terapii jest używana angiografia indocyjaninowa i fluoresceinowa oraz OCT i angio-OCT. Efekty leczenia są zależne od stadium zaawansowania choroby i zastosowanej terapii.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Mędrzycka J, Piotrowicz A, Gołębiewska J, Różycki R. Diagnostyka neowaskularyzacji plamkowej typu 3. Ophthatherapy [Internet]. 30 wrzesień 2021 [cytowane 11 marzec 2025];8(3):153-8. Dostępne na: https://journalsmededu.pl/index.php/ophthatherapy/article/view/1512
Numer
Dział
Diagnostyka
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Yannuzzi LA, Freund KB, Takahashi BS. Review of retinal angiomatous proliferation or type 3 neovascularization. Retina. 2008; 28(3): 375-84.
2. Hartnett ME, Weiter JJ, Garsd A et al. Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol. 1992; 230(1): 11-9. http://doi.org/10.1007/BF00166756.
3. Tsai ASH, Cheung N, Gan ATL et al. Retinal angiomatous proliferation. Surv Ophthalmol. 2017; 62(4): 462-92. http://doi.org/10.1016/j.survophthal.2017.01.
4. Gołębiewska J, Hautz W. Zastosowanie angio-OCT w diagnostyce i terapii okulistycznej – część I. OphthaTherapy. 2016; 3(3): 161-71.
5. Campa C, Harding S, Pearce I et al. Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Eye. 2010; 24: 1585-9. http://doi.org/10.1038/eye.2010.88.
6. Kałużny JJ, Zabel K, Zabel P. Proliferacje naczyniakowate siatkówki – epidemiologia, obraz kliniczny i leczenie. Okulistyka. 2021: 21-6.
7. Bearelly S, Espinosa-Heidmann DG, Cousins SW. The role of dynamic indocyanine green angiography in the diagnosis and treatment of retinal angiomatous proliferation. Br J Ophthalmol. 2008; 92(2): 191-6.
8. Öztaş Z, Menteş J. Retinal Angiomatous Proliferation: Multimodal Imaging Characteristics and Follow-up with Eye-Tracked Spectral Domain Optical Coherence Tomography of Precursor Lesions. Turk J Ophthalmol. 2018; 48(2): 66-9.
9. Rispoli M, Cennamo G, Di Antonio L et al. Imaging Biomarkers in Exudative AMD. Biomedicines. 2021; 9(6): 668.
10. Querques G, Miere A, Souied EH. Optical Coherence Tomography Angiography Features of Type 3 Neovascularization in Age-Related Macular Degeneration. Dev Ophthalmol. 2016; 56: 57-61. http://doi.org/10.1159/000442779. Epub 2016.
11. Boscia F, Parodi MB, Furino C et al. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2006; 244(10): 1224-32. http://doi.org/10.1007/s00417-005-0205-2. Epub 2006.
12. Stoffelns BM, Kramann C, Schoepfer K. Laserfotokoagulation und photodynamische Therapie (PDT) zur Behandlung der retinalen angiomatösen Proliferation (RAP) bei feuchter altersabhängiger Makuladegeneration (AMD) [Laser photocoagulation and photodynamic therapy (PDT) with verteporfin for retinal angiomatous proliferation (RAP) in age-related macular degeneration (AMD)]. Klin Monbl Augenheilkd. 2008; 225(5): 392-6. http://doi.org/10.1055/s-2008-1027251.
13. Rouvas AA, Papakostas TD, Vavvas D et al. Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina. 2009; 29(4): 536-44. http://doi.org/10.1097/IAE.0b013e318196b1de.
14. Krebs I, Krepler K, Stolba U et al. Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone. Graefes Arch Clin Exp Ophthalmol. 2008; 246(2): 237-43. http://doi.org/10.1007/s00417-007-0651-0 . Epub 2007.
15. Nakano S, Honda S, Oh H et al. Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation. Clin Ophthalmol. 2012; 6: 277-82. http://doi.org/10.2147/OPTH.S29718. Epub 2012.
16. Saito M, Iida T, Kano M. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2012; 153(3): 504-14.e1. http://doi.org/10.1016/j.ajo.2011.08.038. Epub 2011.
17. Malamos P, Tservakis I, Kanakis M et al. Long-Term Results of Combination Treatment with Single-Dose Ranibizumab plus Photodynamic Therapy for Retinal Angiomatous Proliferation. Ophthalmologica. 2018; 240(4): 213-21. http://doi.org/10.1159/000487610. Epub 2018.
18. Mantel I, Ambresin A, Zografos L. Retinal angiomatous proliferation treated with a combination of intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin. Eur J Ophthalmol. 2006; 16(5): 705-10. http://doi.org/10.1177/112067210601600507.
19. Hata M, Yamashiro K, Oishi A et al. Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor injections for retinal angiomatous proliferation. Retina. 2017; 37(11): 2069-77. http://doi.org/10.1097/IAE.0000000000001457.
2. Hartnett ME, Weiter JJ, Garsd A et al. Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol. 1992; 230(1): 11-9. http://doi.org/10.1007/BF00166756.
3. Tsai ASH, Cheung N, Gan ATL et al. Retinal angiomatous proliferation. Surv Ophthalmol. 2017; 62(4): 462-92. http://doi.org/10.1016/j.survophthal.2017.01.
4. Gołębiewska J, Hautz W. Zastosowanie angio-OCT w diagnostyce i terapii okulistycznej – część I. OphthaTherapy. 2016; 3(3): 161-71.
5. Campa C, Harding S, Pearce I et al. Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Eye. 2010; 24: 1585-9. http://doi.org/10.1038/eye.2010.88.
6. Kałużny JJ, Zabel K, Zabel P. Proliferacje naczyniakowate siatkówki – epidemiologia, obraz kliniczny i leczenie. Okulistyka. 2021: 21-6.
7. Bearelly S, Espinosa-Heidmann DG, Cousins SW. The role of dynamic indocyanine green angiography in the diagnosis and treatment of retinal angiomatous proliferation. Br J Ophthalmol. 2008; 92(2): 191-6.
8. Öztaş Z, Menteş J. Retinal Angiomatous Proliferation: Multimodal Imaging Characteristics and Follow-up with Eye-Tracked Spectral Domain Optical Coherence Tomography of Precursor Lesions. Turk J Ophthalmol. 2018; 48(2): 66-9.
9. Rispoli M, Cennamo G, Di Antonio L et al. Imaging Biomarkers in Exudative AMD. Biomedicines. 2021; 9(6): 668.
10. Querques G, Miere A, Souied EH. Optical Coherence Tomography Angiography Features of Type 3 Neovascularization in Age-Related Macular Degeneration. Dev Ophthalmol. 2016; 56: 57-61. http://doi.org/10.1159/000442779. Epub 2016.
11. Boscia F, Parodi MB, Furino C et al. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2006; 244(10): 1224-32. http://doi.org/10.1007/s00417-005-0205-2. Epub 2006.
12. Stoffelns BM, Kramann C, Schoepfer K. Laserfotokoagulation und photodynamische Therapie (PDT) zur Behandlung der retinalen angiomatösen Proliferation (RAP) bei feuchter altersabhängiger Makuladegeneration (AMD) [Laser photocoagulation and photodynamic therapy (PDT) with verteporfin for retinal angiomatous proliferation (RAP) in age-related macular degeneration (AMD)]. Klin Monbl Augenheilkd. 2008; 225(5): 392-6. http://doi.org/10.1055/s-2008-1027251.
13. Rouvas AA, Papakostas TD, Vavvas D et al. Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina. 2009; 29(4): 536-44. http://doi.org/10.1097/IAE.0b013e318196b1de.
14. Krebs I, Krepler K, Stolba U et al. Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone. Graefes Arch Clin Exp Ophthalmol. 2008; 246(2): 237-43. http://doi.org/10.1007/s00417-007-0651-0 . Epub 2007.
15. Nakano S, Honda S, Oh H et al. Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation. Clin Ophthalmol. 2012; 6: 277-82. http://doi.org/10.2147/OPTH.S29718. Epub 2012.
16. Saito M, Iida T, Kano M. Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2012; 153(3): 504-14.e1. http://doi.org/10.1016/j.ajo.2011.08.038. Epub 2011.
17. Malamos P, Tservakis I, Kanakis M et al. Long-Term Results of Combination Treatment with Single-Dose Ranibizumab plus Photodynamic Therapy for Retinal Angiomatous Proliferation. Ophthalmologica. 2018; 240(4): 213-21. http://doi.org/10.1159/000487610. Epub 2018.
18. Mantel I, Ambresin A, Zografos L. Retinal angiomatous proliferation treated with a combination of intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin. Eur J Ophthalmol. 2006; 16(5): 705-10. http://doi.org/10.1177/112067210601600507.
19. Hata M, Yamashiro K, Oishi A et al. Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor injections for retinal angiomatous proliferation. Retina. 2017; 37(11): 2069-77. http://doi.org/10.1097/IAE.0000000000001457.